Table 3. Increase in volume of the future liver remnant in the two groups.
| Index | Result | P value | ||||
|---|---|---|---|---|---|---|
| ALPPS group | TACE + PVE group | |||||
| n=38 | P value | n=38 | P value | |||
| Liver hypertrophy time, in day | 12 (8.0–30) | 42 (28.0–131) | <0.001 | |||
| FLR before 1st operation | 462.5 (299.0–666) | 440 (249.0–635) | 0.114 | |||
| △FLR, median (range), in mL | 172 (97.0–457) | 158.5 (3.0–460) | 0.169 | |||
| △FLR/FLR1, median (range), in % | 38 (18.0–104) | 39 (1.0–163) | 0.618 | |||
| △FLR/day, in mL/d | 15.4 (4.8–43.4) | 3.8 (0.1–8.0) | <0.001 | |||
| Tumor volume before the 1st operation, in mL | 451 (18.0–2,493) | 0.408 | 397 (9.0–1,677) | 0.433 | 0.728 | |
| Tumor volume before the 2st operation or the last examination, in mL | 489 (23.0–2,503) | 480 (7.0–2,965) | 0.685 | |||
Liver hypertrophy time: the waiting time between the two operations or the time span from the first stage operation to treatment failure. △FLR: the increase in future liver remnant volume between the two operations. △FLR/FLR1: the increase of future liver remnant volume between the two operations divided by the volume of future liver remnant before the first operation.